1 hour ago
2
David Jagielski, CPA, The Motley Fool
Mon, April 13, 2026 astatine 9:20 AM CDT 3 min read
On April 1, Eli Lilly (NYSE: LLY) and its shareholders received the quality they were eagerly awaiting: the support of the company's GLP-1 pill, Foundayo. While the institution isn't the archetypal retired of the gross with a GLP-1 pill, it's inactive a monolithic maturation accidental for the concern nonetheless. The company's injectable treatment, Zepbound, has already been generating billions successful revenue, and Foundayo whitethorn assistance it scope adjacent much patients.
Could this beryllium the catalyst the healthcare stock, which is down 13% this year, needs to get going?
Will AI make the world's archetypal trillionaire? Our squad conscionable released a study connected the 1 little-known company, called an "Indispensable Monopoly" providing the captious exertion Nvidia and Intel some need. Continue »
Pills are easier and much convenient options for patients than injectables. Plus, galore radical simply don't privation to usage needles and thus, person been waiting for GLP-1 pills to instrumentality instead. Now, with Foundayo approved, this could unfastened up the accidental for Eli Lilly to merchantability to a wider scope of customers, improving upon its already beardown maturation rate.
Last year, the company's gross roseate by 45% to $65.2 billion. The bulk of that maturation was from Zepbound, which generated $13.5 cardinal and roseate by 175% from a twelvemonth ago. Mounjaro, which is simply a GLP-1 cause approved for diabetes, doubled its gross to conscionable nether $23 billion. GLP-1 drugs person been maturation beasts for Eli Lilly, and the anticipation is that a pill volition pb to adjacent amended numbers.
Shares of Eli Lilly got a boost connected quality of Foundayo's approval, but they haven't precisely been soaring. One occupation could beryllium a precocious valuation, arsenic the banal trades astatine much than 40 times trailing earnings, a steep aggregate arsenic the S&P 500 mean is conscionable 24. While the premium whitethorn beryllium justifiable fixed the company's awesome growth, Eli Lilly simply hasn't been the blistery bargain it's been of precocious amid capitalist concerns astir precocious banal prices. But implicit the past 5 years, it's inactive up much than 415% -- the banal whitethorn simply beryllium taking a breather.
With a agleam aboriginal ahead, I judge this tin beryllium an fantabulous banal to own. The institution has promising maturation opportunities successful the GLP-1 space, positive it besides has a affluent and divers pipeline that includes dozens of late-stage trials. Regardless of however it does successful the abbreviated term, Eli Lilly is 1 of the amended healthcare stocks you tin bargain and clasp for the agelong haul.
.png)
English (CA) · 
English (US) · 
Spanish (MX) ·